Menopausal hormone therapy and risk of seropositive rheumatoid arthritis: A nationwide cohort study in Korea
Main finding · Seropositive RAResult — go to the resultHazard ratio 1.12 95 % CI 0.998–1.256Authors' conclusion
The use of MHT did not show a significant impact on the development of RA in postmenopausal women.
Study context
- Population
- Korean women aged > 40 years who consulted a healthcare provider for menopause, 2011–2014; followed up until December 31, 2020138,991 matched pairs
- Exposure
- Menopausal hormone therapy (MHT) vs non-MHT
- MHTn = 138,424
- Outcome
- Incident seropositive rheumatoid arthritis (RA) (ICD-10 M05)
Methodological detailspopulation-based, nationwide, propensity score matched
- Population-based
- Nationwide
- Propensity score matched
Main finding
Seropositive RA
Hazard ratio
1.12
95 % CI 0.998–1.256
Events by group
MHT
0.4 %
567 of 138,424
MHTvs Non-MHT
HR 1.12 (95 % CI 0.998–1.256)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95 % CI) | |
|---|---|---|
| RA with MHT use for ≤ 3 yearsMHT use ≤ 3 years | 1.277 (1.127–1.447) | |
| RA with estrogen/progestogenEstrogen/progestogen | 1.24 (1.05–1.46) | |
| RA with tiboloneTibolone | 1.33 (1.13–1.57) | |
| 0.512Hazard ratio (log scale) |
Original publication
Menopausal hormone therapy and risk of seropositive rheumatoid arthritis: A nationwide cohort study in Korea. Semin Arthritis Rheum. Published 13 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →